NEUROIMMUNOLOGY PATIENT RESPONSE TO COVID-19 OUTBREAK

NEUROIMMUNOLOGY PATIENT RESPONSE TO COVID-19 OUTBREAK

Brief description of study

The purpose of this research study is to understand how our patients with Multiple Sclerosis (MS) and other neuroimmune disorders are being affected by the COVID-19 outbreak. We want to understand how susceptible our patients are to COVID-19. We also want to evaluate the longer-term social and psychological consequences of the pandemic for individuals who have chronic neuroimmune diseases. We are also inviting healthy individuals to participate in this study as controls.

Detailed description of study

This study will employ prospective data collection and review of medical records. It is an observational, non-interventional study. Participants will be provided with a longitudinal set of online questionnaires to assess response to the COVID-19 outbreak. Information surrounding their neurologic diagnosis will be verified from their medical records. A set of surveys will be sent out every 2-4 weeks, and each set of surveys will require approximately 10-30 minutes to complete. There will be 16 total sets of surveys over 52 weeks. No in-person visits or testing are required. Your participation will last for approximately 2 years. 

Additional Information
To participate, please head to: https://redcap.med.upenn.edu/surveys/?s=8YLWXMJJRK

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Both multiple sclerosis patients & healthy participants
  • Age: Between 18 Years - 99 Years
  • Gender: All

Diagnosis of MS, neuromyelitis optica, anti-MOG disease, autoimmune encephalitis, neurosarcoidosis OR lack of neurologic diagnosis (as above) and is a healthy household member of an individual with a qualifying diagnosis.

Updated on 09 Mar 2024. Study ID: 843454
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center